

1. REVLIMID [package insert]. Summit, NJ: Celgene Corp; 2019.
2. Daratumumab [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2019.
3. Data on file. Celgene Corp; 2018.
4. Anderson KC. Therapeutic advances in relapsed or refractory multiple myeloma. *J Natl Compr Canc Netw*. 2013;11(5 suppl):676-679.
5. Hajek R. Strategies for the treatment of multiple myeloma in 2013: moving toward the cure. In: Hajek R, ed. *Multiple Myeloma*. IntechOpen; 2013. doi:10.5772/55366.
6. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. *J Hematol Oncol*. 2009;2:36.
7. Borrello I. Can we change the disease biology of multiple myeloma? *Leuk Res*. 2012;36(suppl 1):S3-S12.
8. POMALYST [package insert]. Summit, NJ: Celgene Corp; 2018.
9. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.3.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed June 25, 2019. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
10. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med*. 2014;371(10):906-917.
11. Facon T, Kumar S, Plesner T, et al. Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA). Presented at: 60th ASH Annual Meeting and Exposition; December 4, 2018; San Diego, CA.

12. Poon ML, Chng WJ. Is complete remission an important therapeutic aim in multiple myeloma? *Cancer Ther.* 2008;6:275-284.
13. Moreau P, Giralt SA. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma. *Leuk Res.* 2012;36:S13-S18.
14. Roschewski M, Korde N, Wu SP, Landgren O. Pursuing the curative blueprint for early myeloma. *Blood.* 2013;122(4):486-490.
15. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. *Nat Rev Cancer.* 2012;12(5):335-348.
16. Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. *Blood.* 2015;125(20):3076-3084.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

